S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
HUGE BUY ALERT: Move Fast, Musk… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Better Than Oil Stocks (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
HUGE BUY ALERT: Move Fast, Musk… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Better Than Oil Stocks (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
HUGE BUY ALERT: Move Fast, Musk… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Better Than Oil Stocks (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Better Than Oil Stocks (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
HUGE BUY ALERT: Move Fast, Musk… (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
Better Than Oil Stocks (Ad)
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
Tax-free status of movie, music and games traded online is on table as WTO nations meet in Abu Dhabi
NASDAQ:EVGN

Evogene (EVGN) Stock Price, News & Analysis

$0.89
-0.01 (-1.11%)
(As of 02/23/2024 ET)
Today's Range
$0.89
$0.92
50-Day Range
$0.67
$0.98
52-Week Range
$0.45
$1.44
Volume
89,432 shs
Average Volume
247,427 shs
Market Capitalization
$36.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.62

Evogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
307.5% Upside
$3.62 Price Target
Short Interest
Healthy
0.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Evogene in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.47) to ($0.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.01 out of 5 stars

Medical Sector

599th out of 940 stocks

Agricultural Chemicals Industry

7th out of 9 stocks


EVGN stock logo

About Evogene Stock (NASDAQ:EVGN)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

EVGN Stock Price History

EVGN Stock News Headlines

The Retirement of Your Dreams Awaits You…
Imagine it's 2025 and you have the financial freedom to pursue any of your biggest goals. All of this because YOU decided to take action in 2024. The Bitcoin Halving in 2024 could change your life forever...And the strategies outlined in the Crypto Retirement Blueprint will give you what you need to be able to crush the upcoming halving cycle bull run, and potentially retire quickly in wealth.
The perfect AI stock under $10
Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion. However, new AI technology has the potential to make the process up to 1000 times faster. This #1 AI company is at the forefront of it all.
Recap: Evogene Q3 Earnings
Evogene Reports Third Quarter 2023 Financial Results
Evogene earnings: here's what Wall Street expects
A Preview Of Evogene's Earnings
Evogene (EVGN) Receives a Buy from Lake Street
Evogene Reports Second Quarter 2023 Financial Results
Evogene (EVGN) Reports Q2 Loss, Lags Revenue Estimates
See More Headlines
Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2023
Today
2/25/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:EVGN
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.62
High Stock Price Target
$6.00
Low Stock Price Target
$1.85
Potential Upside/Downside
+307.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-26,640,000.00
Net Margins
-354.35%
Pretax Margin
-391.86%

Debt

Sales & Book Value

Annual Sales
$1.67 million
Book Value
$0.84 per share

Miscellaneous

Free Float
38,166,000
Market Cap
$36.58 million
Optionable
Optionable
Beta
1.46
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ofer Haviv CPA (Age 58)
    CEO & President
    Comp: $437k
  • Mr. Mark Kapel (Age 47)
    Chief Technology Officer
    Comp: $276k
  • Mr. Sassi Masliah (Age 45)
    Vice President of Corporate Development
    Comp: $245k
  • Dr. Nir Arbel (Age 44)
    Chief Product Officer
    Comp: $247k
  • Dr. Brian Ember (Age 48)
    Chief Executive Officer of AgPlenus Ltd
    Comp: $294k
  • Mr. Yaron Eldad (Age 59)
    Chief Financial Officer
  • Rachel Pomerantz Gerber
    Head of Investor Relations
  • Ms. Liat Foigel Wejgman
    Vice President of Human Resources
  • Mr. Eyal Ronen
    Executive Vice President of Business Development
  • Dr. Elran Hillel Haber M.B.A. (Age 44)
    Ph.D., Chief Executive Officer of Biomica Ltd
    Comp: $287k














EVGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Evogene stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings
or view top-rated stocks.

What is Evogene's stock price target for 2024?

3 Wall Street research analysts have issued 12 month price objectives for Evogene's shares. Their EVGN share price targets range from $1.85 to $6.00. On average, they predict the company's share price to reach $3.62 in the next year. This suggests a possible upside of 307.5% from the stock's current price.
View analysts price targets for EVGN
or view top-rated stocks among Wall Street analysts.

How have EVGN shares performed in 2024?

Evogene's stock was trading at $0.84 at the start of the year. Since then, EVGN shares have increased by 5.7% and is now trading at $0.8875.
View the best growth stocks for 2024 here
.

When is Evogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our EVGN earnings forecast
.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) released its quarterly earnings data on Wednesday, November, 15th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.09. The biotechnology company earned $3.77 million during the quarter, compared to analyst estimates of $1.09 million. Evogene had a negative trailing twelve-month return on equity of 62.26% and a negative net margin of 354.35%. During the same quarter in the previous year, the company earned ($0.16) EPS.

What other stocks do shareholders of Evogene own?
Who are Evogene's major shareholders?

Evogene's stock is owned by a variety of retail and institutional investors. Top institutional investors include Simplex Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVGN) was last updated on 2/25/2024 by MarketBeat.com Staff